GLP-1 receptor agonists and dipeptidyl peptidase 4 inhibitors should be considered as second-line treatments in individual cases, having an important role in the treatment of pasireotide-induced hyperglycemia. This evidence concerns the gene GLP1R and Hyperglycemia.